Cargando…

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma

Resistance to epidermal growth factor receptor (EGFR)-targeted therapy is insufficiently understood in head and neck squamous cell carcinoma (HNSCC), entailing the lack of predictive biomarkers. Here, we studied resistance-mediating EGFR ectodomain and activating RAS mutations by next-generation seq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braig, Friederike, Voigtlaender, Minna, Schieferdecker, Aneta, Busch, Chia-Jung, Laban, Simon, Grob, Tobias, Kriegs, Malte, Knecht, Rainald, Bokemeyer, Carsten, Binder, Mascha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190002/ https://www.ncbi.nlm.nih.gov/pubmed/27119512 http://dx.doi.org/10.18632/oncotarget.8943

Ejemplares similares

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
por: Braig, Friederike, et al.
Publicado: (2015)

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014)

Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling
por: Tintelnot, Joseph, et al.
Publicado: (2020)

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
por: Rossi, Alessandra, et al.
Publicado: (2019)

Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests
por: Kriegs, Malte, et al.
Publicado: (2016)

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
por: Möckelmann, Nikolaus, et al.
Publicado: (2016)

The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective
por: Rieckmann, Thorsten, et al.
Publicado: (2019)

Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines
por: Busch, Chia-Jung, et al.
Publicado: (2016)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products
por: Gurvich, Olga L., et al.
Publicado: (2020)

The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids
por: Fu, Jingyuan, et al.
Publicado: (2015)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
por: Oberle, Anna, et al.
Publicado: (2017)

ICMJE authorship criteria are not met in a substantial proportion of manuscripts submitted to Biochemia Medica
por: Šupak-Smolčić, Vesna, et al.
Publicado: (2015)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
por: Tintelnot, Joseph, et al.
Publicado: (2022)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
por: Chan, Wing-Lok, et al.
Publicado: (2014)

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature
por: Guo, Sheng, et al.
Publicado: (2016)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
por: Veluchamy, John Pradeep, et al.
Publicado: (2016)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
por: van Helden, Erik J., et al.
Publicado: (2019)

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
por: Tsai, Hsiang-Lin, et al.
Publicado: (2023)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations
por: Gollins, Simon, et al.
Publicado: (2017)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
por: Chen, Shang-Hung, et al.
Publicado: (2019)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
por: Tao, Huimin, et al.
Publicado: (2022)

Monocyte activation and acquired autoimmune protein S deficiency promote disseminated intravascular coagulation in a patient with primary antiphospholipid syndrome
por: Beckmann, Lennart, et al.
Publicado: (2021)

Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma
por: Schieferdecker, Aneta, et al.
Publicado: (2020)

Right Atrial Thrombosis in Antiphospholipid Syndrome with Secondary Immune Thrombocytopenia
por: Voigtlaender, Minna, et al.
Publicado: (2015)

mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
por: Wang, Zhiyong, et al.
Publicado: (2014)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
por: Yang, Jing, et al.
Publicado: (2017)

Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis
por: Zheng, Peng, et al.
Publicado: (2018)

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
por: Guren, Tormod Kyrre, et al.
Publicado: (2017)

Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer
por: Xu, Xiaojing, et al.
Publicado: (2023)

RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources
por: Wu, Bin, et al.
Publicado: (2017)

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc
por: Yu, Yiyi, et al.
Publicado: (2016)

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
por: Toledo, Rodrigo A., et al.
Publicado: (2016)

Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer
por: Wei, Li, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bd0qd7pa65gjctslqv3eghdphl